A Phase II Study of Weekly ABRAXANE(R) (Nab-paclitaxel) for Patients With Advanced NSCLC With EGFR Mutations Following Front-line Therapy With EGFR Tyrosine Kinase Inhibitors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Oct 2017 Planned primary completion date changed from 1 Jan 2018 to 23 May 2018.
- 02 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.